Welcome to our dedicated page for Anavex Life Scie SEC filings (Ticker: AVXL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Anavex Life Sciences Corp. filings document material events for a Nevada clinical-stage biopharmaceutical issuer with common stock listed on Nasdaq under AVXL. Recent Form 8-K disclosures cover financial results releases, securities registration details for its common stock, and corporate governance matters involving board appointments, executive employment arrangements, and leadership changes.
The filings also record regulatory disclosures tied to blarcamesine, including European Medicines Agency review matters for early Alzheimer’s disease and related press-release exhibits. These documents provide formal records of the company’s public-company reporting, clinical-development communications, governance actions, compensation arrangements, and capital-market security status.
Anavex Life Sciences Corp. reported that Nasdaq has notified the company it is out of compliance with Nasdaq Listing Rule 5250(c)(1) because it did not file its Form 10‑Q for the quarter ended March 31, 2026 on time. The company’s shares remain listed on the Nasdaq Global Select Market and continue trading under the symbol AVXL.
Anavex has until July 20, 2026 to submit a plan explaining how it will regain compliance. If Nasdaq accepts the plan, it may allow up to 180 days from the Form 10‑Q due date, through November 16, 2026, for Anavex to file and cure the delinquency. If Nasdaq does not accept the plan, the company could face a delisting process, though it would be able to appeal to a Nasdaq Hearings Panel. Anavex states it is working to complete the Form 10‑Q and submit its compliance plan.
Anavex Life Sciences Corp. reported the departure of its Chief Operating Officer, Felix Lauscher, effective May 11, 2026, as part of a broader reorganization of duties following the appointment of Dr. Terrie Kellmeyer as Interim Chief Executive Officer. Lauscher had served as COO since March 1, 2026.
Under his employment agreement, he received a prorated portion of his $264,000 annual base salary. He had been granted 50,000 stock options; 45,833 were forfeited upon departure, while 4,167 options that vested on March 31, 2026 remain exercisable until August 9, 2026 at $4.69 per share under the company’s Omnibus Incentive Plan. In connection with his departure, he was offered an additional two weeks of compensation at his base salary level in exchange for signing and not revoking a general release.
ANAVEX LIFE SCIENCES CORP. Interim CEO Terrie Kellmeyer has filed an initial Form 3 showing holdings of stock options rather than recent trades. The filing lists three option grants over common stock: options covering 50,000 shares with an exercise price of $8.58 expiring on March 31, 2035; 7,500 shares at $5.36 expiring on February 20, 2034; and 46,668 shares at $7.21 expiring on November 30, 2033, all held directly.
Footnotes clarify vesting: the 50,000-share grant includes 35,001 fully vested options and 11,667 that vest in two substantially equal tranches on June 30, 2026 and September 30, 2026. The 7,500-share grant includes 2,500 fully vested options and 5,000 that vest in two equal tranches based on performance milestones. Another 50,000-share grant includes 25,000 fully vested options and 25,000 that will vest in two equal performance-based tranches.
Anavex Life Sciences Corp. notified the SEC that it cannot timely file its Quarterly Report on Form 10-Q for the period ended March 31, 2026 by the prescribed May 11, 2026 due date. The delay is due to an independent Special Committee review after the termination of the prior CEO on April 30, 2026, and the appointment of an Interim CEO on May 4, 2026. The Company says the Special Committee and management are working to complete their review so the Form 10-Q can be filed.
Anavex Life Sciences Corp. reported a leadership change and a pending filing delay. A special committee of independent directors ended the employment of President and Chief Executive Officer Christopher Missling, PhD, for Cause under his employment agreement and asked him to resign from the Board.
The Board appointed Terrie Kellmeyer, PhD, a veteran drug development executive and former Senior Vice President of Clinical Development at Anavex, as Interim Chief Executive Officer effective May 4, 2026. Her compensation includes a $500,000 base salary, a target bonus equal to 30% of salary, a $150,000 signing bonus, and 200,000 stock options. The company also expects to file a Form 12b-25 to extend the deadline for its Form 10-Q for the quarter ended March 31, 2026.
ANAVEX LIFE SCIENCES CORP. director Axel Paeger filed an initial Form 3, which is a statement of beneficial ownership for company insiders. The filing shows no reported transactions, exercises, gifts, or restructurings and contains no derivative holdings or position details in this excerpt.
Anavex Life Sciences Corp ownership filing shows 0 shares beneficially owned by The Vanguard Group as amended. The filing explains an internal realignment within Vanguard that led certain subsidiaries to report separately in reliance on SEC Release No. 34-39538, and states Vanguard reports no beneficial ownership in this class.
Anavex Life Sciences Corp. reported that it has withdrawn its application for EU marketing authorization of its lead drug candidate blarcamesine as an add-on therapy for adults with early Alzheimer’s disease. The application had been under review by the European Medicines Agency’s Committee for Medicinal Products for Human Use.
The withdrawal follows CHMP feedback indicating it would not be in a position to issue a positive opinion at this time. Anavex states it remains committed to the ongoing clinical development of blarcamesine and plans to gather additional data and conduct further analyses to address the points raised by the CHMP.
Anavex Life Sciences Corp. reported a governance update, announcing that its Board of Directors appointed Dr. Axel Paeger as a new director, effective February 23, 2026, to fill an existing vacancy. He will receive compensation consistent with other non-employee directors.
The Board determined that Dr. Paeger qualifies as an independent director under Securities Exchange Act rules and Nasdaq Capital Market listing standards. The company stated there are no special arrangements connected to his appointment and no related-party transactions requiring disclosure. A related press release dated February 23, 2026 was furnished as an exhibit.
Anavex Life Sciences Corp. reported a narrower net loss for the three months ended December 31, 2025 as it continued developing CNS drug candidates without generating product revenue. Net loss was $5.7 million, improved from $12.1 million a year earlier, driven by sharply lower research and development and general and administrative expenses.
Operating expenses fell to $6.8 million from $13.6 million, reflecting reduced clinical trial and share-based compensation costs. Other income of $1.1 million, mainly interest on cash, partly offset expenses. Anavex strengthened its balance sheet by raising $36.3 million through its 2025 at-the-market Sales Agreement, issuing about 6.0 million new shares.
Cash and cash equivalents rose to $131.7 million as of December 31, 2025, up from $102.6 million at September 30, 2025. Management states this working capital should fund operations for more than 12 months, even as the company expects continued negative operating cash flows while advancing programs in Alzheimer’s disease, Parkinson’s disease, Rett syndrome, schizophrenia, and other CNS indications.